Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 8, 2009

Novo Nordisk Pays ZymoGenetics $24M Up Front for Expanded Rights to IL-21 mAb Technology

  • Novo Nordisk negotiated a deal with ZymoGenetics with $24 million up front for extended development rights to the latter’s IL-21 mAb IP. The agreement, which covers a pre-IND candidate, adds North America to Novo Nordisk’s existing non-U.S. license, obtained back in 2001.

    The company now has global rights to develop IL-21 antibodies. A Phase I trial with the lead IL-21 mAb is expected to start in 2010. ZymoGenetics could receive another $157.5 million in milestone payments relating to development of this candidate for autoimmune and inflammatory diseases plus future sales royalties. The company retains an option to co-promote the IL-21 mAb in the U.S. in exchange for a $10 million fixed fee and a 15% contribution to the costs of Phase III trials. Triggering the option would also make ZymoGenetics eligible for higher royalties on future sales of the drug.

    “It was important for us to secure the worldwide rights to the IL-21 mAb project as well as worldwide patent rights to IL-21 antibodies,” stresses Mads Krogsgaard Thomsen, Novo Nordisk’s evp and CSO. “Novo Nordisk is currently building a pipeline of products to treat autoimmune and inflammatory diseases such as rheumatoid arthritis, lupus, and inflammatory bowel disease.”

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »